It’s time for an important update on the Cell and Gene therapy landscape.
Increasingly we are seeing novel technologies being developed in academia and being licensed to biotech companies for use in conjunction with their products.
This cross fertilisation of ideas is a good use of both parties expertise, which will hopefully benefit more patients in the long run.
As we seek improved performance of cell therapy products in terms of potency and persistence, safety becomes an ever more important aspect to watch out for, especially if gene editing is involved.
In this latest post on the C> niche, we explore a number of pertinent issues and offer an update on a company not long out of stealth mode…